Industry-leading amplicon solution facilitates targeted
next-generation sequencing in multiple application areas
CARLSBAD, Calif. & SAN DIEGO--(BUSINESS WIRE)--Jan. 8, 2018--
Thermo Fisher Scientific and Illumina, Inc. (NASDAQ: ILMN) today
announced they have signed a commercial agreement that enables Illumina
to sell Ion AmpliSeq technology to researchers who conduct scientific
studies on Illumina’s next-generation sequencing (NGS) platforms. The
best-in-class amplicon technology is highly effective in capturing DNA
and RNA from minute amounts of samples for application in multiple areas
of research.
Under the agreement, Thermo Fisher will provide Illumina with Ion
AmpliSeq technology for research use. Illumina will sell the product
directly to its customers under the name AmpliSeq for Illumina. Thermo
Fisher will continue to sell Ion AmpliSeq chemistry for both IVD and RUO
applications to Ion Torrent NGS customers, and retains the right to make
the technology available on other next-generation sequencing platforms.
“Thermo Fisher expects standardization on the AmpliSeq technology will
have a profound impact on disease research and encourage greater
collaboration among the NGS community,” said Joydeep Goswami, President
of Clinical Next-Generation Sequencing and Oncology for Thermo Fisher
Scientific. “Through this agreement, a much larger base of research
customers can now leverage Ion AmpliSeq technology’s benefits, while
Thermo Fisher continues its commitment to Ion Torrent targeted
sequencing solutions for the research market and accelerates its focus
and forward momentum in the clinical space.”
The agreement enables Illumina customers to utilize targeted
resequencing as a follow-up to larger-scale exome and whole genome
discovery studies. Ultimately, the agreement supports both
organizations’ commitment to drive scientific advancement in human
disease research by providing complete NGS workflow solutions.
“This partnership represents a significant step forward enabling a high
performing, flexible amplicon chemistry for use on Illumina’s
market-leading portfolio of sequencing systems,” said Mark Van Oene,
Chief Commercial Officer for Illumina. “By expanding access to AmpliSeq
chemistry to existing customers, we are enabling them to do even more
with their systems.”
Introduced to the market in 2011, Ion AmpliSeq technology was developed
to facilitate amplicon sequencing on the Ion Torrent NGS systems. The
technology leverages highly multiplexed polymerase chain reaction (PCR)
to quickly and easily capture DNA or RNA targets from very limited
samples. It has since proven to be a highly desired and effective NGS
amplicon sequencing solution for its ease-of-use, scalability, efficient
workflow and ability to provide trusted data in multiple NGS research
application areas. To date, more than 1,100 Ion AmpliSeq technology
studies have been published in peer-reviewed scientific journals.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science,
with revenues of more than $20 billion and approximately 65,000
employees globally. Our mission is to enable our customers to make the
world healthier, cleaner and safer. We help our customers accelerate
life sciences research, solve complex analytical challenges, improve
patient diagnostics, deliver medicines to market and increase laboratory
productivity. Through our premier brands – Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we
offer an unmatched combination of innovative technologies, purchasing
convenience and comprehensive services. For more information, please
visit www.thermofisher.com.
About Illumina
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical, and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
follow @illumina.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and
uncertainties. These forward-looking statements are based on our
expectations as of the date of this release and may differ materially
from actual future events or results. Among the important factors that
could cause actual results to differ materially from those in any
forward-looking statements are (i) our ability to further develop and
commercialize our instruments and consumables, and to deploy new
products, services and applications, and expand the markets for our
technology platforms; (ii) our ability to manufacture robust
instrumentation and consumables; (iii) our ability to successfully
identify and integrate acquired technologies, products or businesses;
(iv) the future conduct and growth of the business and the markets in
which we operate; and (v) challenges inherent in developing,
manufacturing, and launching new products and services, together with
other factors detailed in our filings with the Securities and Exchange
Commission, including our most recent filings on Forms 10-K and 10-Q, or
in information disclosed in public conference calls, the date and time
of which are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or confirm
analysts’ expectations, or to provide interim reports or updates on the
progress of the current quarter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180108006946/en/
Source: Illumina, Inc.
Thermo Fisher Scientific
Mauricio Minotta
+1 760 929 2456
+1
760 805 5266 (mobile)
mauricio.minotta@thermofisher.com
or
Illumina
Eric
Endicott
+ 1 858 255 5645
+ 1 858 263 6428 (mobile)
eendicott@illumina.com